

**Press Release**

**2016-06-27**

**Xbrane introduces incentive program**

Xbrane has introduced an incentive program for the remainder of 2016 which would entitle employees to newly issued shares in Xbrane Biopharma AB upon fulfilment of defined critical targets for the company. The incentive program could result in a maximum issuance of 22 000 new shares in Xbrane Biopharma AB, i.e. a potential maximum dilution of 0,47%. The final issuance of any shares under this program will be subject to approval at the AGM 2017 by shareholders holding not less than nine-tenths of both the votes and the shares represented at the general meeting according to chapter 16 of the Swedish Companies Act.

**About Xbrane**

*Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Complex Generics. Xbrane has world leading expertise in developing generics for injectable controlled release drugs and proprietary high yield protein expression technology for the development of biosimilars. The goal is to become a global leader within the company's portfolio of High Demand Complex Generics. Xbrane's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3<sup>rd</sup> under the name XBRANE and Avanza Bank AB is Xbrane's certified advisor. For more information see [www.xbrane.com](http://www.xbrane.com).*

**For further information, please contact:**

Martin Amark

Chief Executive Officer

M: +46 (0) 763-093 777

E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)